Posted by Michael Wonder on 25 Aug 2024
Abata Therapeutics receives FDA fast track designation for ABA-101 for the treatment of progressive multiple sclerosis
22 August 2024 - Abata Therapeutics today announced that the US FDA has granted fast track designation for ABA-101 for the treatment of patients with progressive multiple sclerosis.
The FDA recently cleared ABA-101’s Investigational new drug application, and initiation of a first in human Phase I study is imminent.
